Treatment with once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) triple therapy appears to be more efficacious in reducing severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) than the standard twice-daily inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination of budesonide plus formoterol (Symbicort). This was among the findings of a post-hoc analysis of the FULFIL trial presented at CHEST 2021, the American College of Chest Physicians annual meeting. Study author, Reynold Panettieri Jr., MD, vice chancellor for Translational Medicine and science director of Rutgers Institute for Translational Medicine in New Brunswick, New Jersey, discusses the findings and clinical implications of the analysis. To read the full story.
Recent Posts
- What leaving World Health Organization would mean for US.
- Fears of devastation across NJ health, scientific research if Trump cuts proceed.
- Rutgers Health scores $686K grant to study effects of medicinal cannabis use.
- Bird Flu Basics From a Rutgers Health Infectious Disease Expert.
- NJACTS Community Engagement Core COVID-19 Resources
Categories
- News (2,381)
- Publication (1)